Idiotype vaccine following EPOCH-rituximab treatment in untreated mantle cell lymphoma.

被引：0
|
作者：
Wilson, WH [1 ]
Neelapu, S [1 ]
White, T [1 ]
Hegde, U [1 ]
Pittaluga, S [1 ]
Hakim, F [1 ]
Stetler-Stevenson, M [1 ]
Frye, R [1 ]
Steinberg, S [1 ]
Jaffe, ES [1 ]
Gress, R [1 ]
Staudt, L [1 ]
Janik, J [1 ]
Kwak, L [1 ]
机构：
[1] NCI, Ctr Canc Res, Bethesda, MD 20892 USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
608
引用
收藏
页码：162A / 162A
页数：1
相关论文
共 50 条
  • [1] Idiotype vaccine and dose-adjusted EPOCH-rituximab treatment untreated mantle cell lymphoma: Preliminary report on clinical outcome and analysis of immune response.
    Wilson, WH
    Neelapu, S
    Rosenwald, A
    White, T
    Dunleavy, K
    Pittaluga, S
    Hakim, F
    Stetler-Stevenson, M
    Steinberg, S
    Jaffe, ES
    Gress, R
    Wright, G
    Staudt, L
    Janik, J
    Kwak, L
    BLOOD, 2003, 102 (11) : 105A - 106A
  • [2] Eleven-Year Follow-up of Idiotype Vaccine and DA-EPOCH-Rituximab in Untreated Mantle Cell Lymphoma: Correlation of Survival with Idiotype Immune Response
    Grant, Cliona
    Neelapu, Sattva S.
    Kwak, Larry W.
    Dunleavy, Kieron
    White, Therese
    Miller, Barry W.
    Jaffe, Elaine S.
    Steinberg, Seth M.
    Bird, Brian Healey
    Wilson, Wyndham H.
    BLOOD, 2011, 118 (21) : 1164 - 1165
  • [3] Burkitt lymphoma responds to EPOCH-rituximab
    不详
    EUROPEAN JOURNAL OF CANCER, 2007, 43 (03) : 470 - 470
  • [4] Dose-adjusted EPOCH-rituximab is highly effective in the GCB and ABC subtypes of untreated diffuse large B-cell lymphoma.
    Wilson, WH
    Dunleavy, K
    Pittaluga, S
    Grant, N
    Steinberg, S
    Raffeld, M
    Chabner, B
    Grossbard, M
    Jaffe, E
    Staudt, L
    Janik, J
    BLOOD, 2004, 104 (11) : 49A - 49A
  • [5] Cladribine plus rituximab for the initial treatment of mantle cell lymphoma.
    Pindyck, T.
    Spurgeon, S. E.
    Okada, C. Y.
    Epner, E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Efficiency of rituximab plus DRAP in the treatment of patients with mantle cell lymphoma.
    Jaccard, A
    Touati, M
    Gachard, N
    Chaury, MP
    Remenieras, L
    Turlure, P
    Bordessoule, D
    BLOOD, 2002, 100 (11) : 315B - 315B
  • [7] Study On The Fertility Status Of Females With Primary Mediastinal B-Cell Lymphoma Following Treatment With Dose-Adjusted EPOCH-Rituximab
    Gharwan, Helen
    Dunleavy, Kieron
    Shovlin, Margaret
    Fojo, Antonio T.
    Fleisher, Thomas A.
    Wilson, Wyndham H.
    Grant, Cliona
    BLOOD, 2013, 122 (21)
  • [8] Personalized recombinant Idiotype vaccination after chemotherapy as initial treatment for mantle cell lymphoma.
    Leonard, J
    Vose, J
    Timmerman, J
    Levy, R
    Ingolia, D
    Denney, D
    Coleman, M
    Kunkel, L
    BLOOD, 2002, 100 (11) : 312B - 312B
  • [9] Potent single agent activity and tumor selectivity of bortezomib in mantle cell lymphoma: First impressions from a randomized phase II study of EPOCH-rituximab-bortezomib in untreated mantle cell lymphoma.
    Wiestner, A
    Dunleavy, K
    Rizzatti, EG
    Liu, H
    Marti, GE
    White, T
    Wilson, W
    BLOOD, 2005, 106 (11) : 266B - 266B
  • [10] RITUXIMAB OF MAINTENANCE IN MANTLE CELL LYMPHOMA. EXPERIENCE OF A CENTRE
    Quintana Ana, Sanchez
    Cristina, Notario
    Carmen, Marrero
    Nuria, Hernanz
    Pablo, Rios
    Joaquin, Brena
    Hector, Gonzalez
    Ana, Cabello
    Ana, Oliva
    Ana, Leon
    Mario, Rios
    Alexander, Figueroa
    Patricia, Hernandez
    Yaxiraxi, Lorenzo
    Alejandro, Marin
    Maria Carmen, Mesa
    HAEMATOLOGICA, 2016, 101 : 227 - 227
12345